CD180

Summary

CD180 (CD180 molecule, HGNC:6726) is a protein-coding gene on chromosome 5q12.3, encoding CD180 antigen (Q99467). Pattern recognition receptor predominantly expressed on B-cells, dendritic cells, and certain monocytes/macrophages, structurally resembling Toll-like receptors (TLRs) that plays a role in modulating immune responses.

CD180 is a cell surface molecule consisting of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. The extracellular LRR is associated with a molecule called MD-1 and form the cell surface receptor complex, RP105/MD-1. It belongs to the family of pathogen receptors, Toll-like receptors (TLR). RP105/MD1, by working in concert with TLR4, controls B cell recognition and signaling of lipopolysaccharide (LPS), a membrane constituent of Gram-negative bacteria.

Source: NCBI Gene 4064 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 106 total
• MANE Select transcript: NM_005582

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6726
Approved symbol	CD180
Name	CD180 molecule
Location	5q12.3
Locus type	gene with protein product
Status	Approved
Aliases	RP105, Ly78
Ensembl gene	ENSG00000134061
Ensembl biotype	protein_coding
OMIM	602226
Entrez	4064

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 retained_intron

ENST00000256447, ENST00000515027

RefSeq mRNA: 1 — MANE Select: NM_005582 NM_005582

CCDS: CCDS3992

Canonical transcript exons

ENST00000256447 — 3 exons

Exon	Start	End
ENSE00000750451	67185851	67186017
ENSE00000837138	67179613	67184585
ENSE00000837139	67196552	67196799

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 86.70.

FANTOM5 (CAGE): breadth broad, TPM avg 5.8438 / max 446.0082, expressed in 413 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
61971	5.8438	413

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	86.70	silver quality
lymph node	UBERON:0000029	85.69	gold quality
leukocyte	CL:0000738	85.47	gold quality
monocyte	CL:0000576	85.44	gold quality
mononuclear cell	CL:0000842	85.26	gold quality
granulocyte	CL:0000094	83.26	gold quality
spleen	UBERON:0002106	80.90	gold quality
vermiform appendix	UBERON:0001154	80.21	gold quality
bone marrow cell	CL:0002092	77.46	gold quality
bone marrow	UBERON:0002371	76.87	gold quality
caecum	UBERON:0001153	76.48	gold quality
blood	UBERON:0000178	76.18	gold quality
superficial temporal artery	UBERON:0001614	74.85	silver quality
trabecular bone tissue	UBERON:0002483	74.50	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.35	silver quality
tonsil	UBERON:0002372	73.43	gold quality
triceps brachii	UBERON:0001509	70.19	gold quality
gluteal muscle	UBERON:0002000	70.07	gold quality
ileal mucosa	UBERON:0000331	69.83	silver quality
rectum	UBERON:0001052	69.68	gold quality
epithelium of nasopharynx	UBERON:0001951	69.66	silver quality
olfactory bulb	UBERON:0002264	67.90	gold quality
type B pancreatic cell	CL:0000169	67.63	gold quality
upper arm skin	UBERON:0004263	67.39	gold quality
placenta	UBERON:0001987	66.73	gold quality
periodontal ligament	UBERON:0008266	66.25	gold quality
diaphragm	UBERON:0001103	66.07	gold quality
smooth muscle tissue	UBERON:0001135	65.99	gold quality
buccal mucosa cell	CL:0002336	65.93	gold quality
gall bladder	UBERON:0002110	65.60	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.70
E-CURD-89	no	109.68

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

28 targeting CD180, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-8064	99.45	66.92	875
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-4646-3P	98.65	66.98	693
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-3928-5P	98.50	67.48	980
HSA-MIR-6806-3P	98.50	67.31	980
HSA-MIR-326	98.25	66.44	1565
HSA-MIR-4433A-3P	97.75	62.82	1435
HSA-MIR-1226-3P	97.51	66.32	1063
HSA-MIR-6796-5P	95.37	66.08	1120
HSA-MIR-3672	94.46	65.67	646
HSA-MIR-6864-3P	94.46	65.97	625

Literature-anchored findings (GeneRIF, showing 23)

• RP105 regulated TLR4 signaling in dendritic cells (PMID:15852007)
• Expression of RP105 and TLR4 is altered on PBC monocytes, which appear to be hypersensitive to LPS, resulting in increased secretion of pro-inflammatory cytokines. (PMID:17448566)
• RP105 cross-linkaage enhanced B-lymphocyte proliferation, TLR9 expression, and growth. (PMID:20133206)
• Lower mRNA expression of LY64 was detected in gingival tissue of chronic periodontitis patients compared to healthy controls. (PMID:20233331)
• Data show that CD180, CD284 and CD14 expression is higher on normal B cells than on CD19+ B-cell chronic lymphocytic leukaemia cells. (PMID:20430725)
• Both mouse and human RP105/MD-1 exhibit dimerization of the 1:1 RP105/MD-1 complex, demonstrating a novel organization. (PMID:21959264)
• IL-4 failed to up-regulate expression of RP105 at the cell surface. In conclusion, the anti-inflammatory actions of IL-4 occur independently of IL-10, RP105, and the kinase activity of RIPK2 (PMID:22484241)
• Data indicate that TLR9-signaling as a crucial factor for turning retinoic acid (RA) into a strong stimulator of RP105-mediated B-cell proliferation. (PMID:23103284)
• we address of monocytes functional status through assessment of the patterns of expression of Fcgamma receptors CD64, CD32, CD16 and CD180 receptor on monocytes from CLL patients and healthy individuals using specific mAbs and flow cytometry. (PMID:25802446)
• Since MEC1 cells are derived from a CLL patient with mutated IGVH genes (M-CLL) negative correlation between CD180 and CD32 expression on cycling MEC1 cells could be limited to M-CLL. (PMID:25879560)
• the close association between the increased proportion of CD180-negative B cells and the activation of IFN-alpha signaling in Systemic lupus erythematosus, is reported. (PMID:26277892)
• By associating with PIM-1L, CD180 can thus obtain autonomous signaling capabilities, and this complex is then channeling inflammatory signals into B cell survival programs (PMID:26555723)
• CD180 expression is significantly upregulated in human masticatory mucosa during wound healing (PMID:28005267)
• Our data strongly support the use of CCR2 and CD180 mRNAs as whole blood pharmacodynamic (PD)biomarkers for BRD4 inhibitors, especially in situations where paired tumor biopsies are unavailable. In addition, they can be used as tumor-based PD biomarkers for hematologic tumors. (PMID:28073847)
• combination of signals via CD150 and CD180 leads to blocking of pro-survival pathways that may be a restraining factor for neoplastic CLL B cells propagation in more than 50% of CLL cases where these receptors are coexpressed (PMID:28982149)
• Calcitriol regulates immune genes CD14 and CD180 to modulate LPS responses in human trophoblasts. (PMID:29089453)
• CD150 and CD180 receptors may modulate transcriptional program in lymphocytic leukemia cells by regulating the transcription factor expression levels (PMID:29284783)
• Silencing Cd180 results in increased phagocytosis while tempering the production of the proinflammatory cytokine TNF during Borrelia burgdorferi infection. (PMID:29511161)
• The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study. (PMID:33455071)
• CD150 and CD180 are negative regulators of IL-10 expression and secretion in chronic lymphocytic leukemia B cells. (PMID:33904315)
• Toll-Like Receptor Homolog CD180 Expression Is Diminished on Natural Autoantibody-Producing B Cells of Patients with Autoimmune CNS Disorders. (PMID:34124274)
• Cell surface expression of human RP105 depends on N-glycosylation of MD-1. (PMID:35849076)
• The role of CD180 in hematological malignancies and inflammatory disorders. (PMID:37460961)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cd180	ENSDARG00000093750
mus_musculus	Cd180	ENSMUSG00000021624
rattus_norvegicus	Cd180	ENSRNOG00000010266

Paralogs (22): IGFALS (ENSG00000099769), TLR8 (ENSG00000101916), LRRC17 (ENSG00000128606), RXFP2 (ENSG00000133105), TLR4 (ENSG00000136869), TLR2 (ENSG00000137462), LRRC32 (ENSG00000137507), LRRC3 (ENSG00000160233), LRRC53 (ENSG00000162621), TLR3 (ENSG00000164342), VASN (ENSG00000168140), RXFP1 (ENSG00000171509), NRROS (ENSG00000174004), TLR10 (ENSG00000174123), TLR1 (ENSG00000174125), TLR6 (ENSG00000174130), LRRC3B (ENSG00000179796), TSKU (ENSG00000182704), TLR5 (ENSG00000187554), TLR7 (ENSG00000196664), LRIT2 (ENSG00000204033), LRRC3C (ENSG00000204913)

Protein

Protein identifiers

CD180 antigen — Q99467 (reviewed: Q99467)

Alternative names: Lymphocyte antigen 64, Radioprotective 105 kDa protein

All UniProt accessions (1): Q99467

UniProt curated annotations — full annotation on UniProt →

Function. Pattern recognition receptor predominantly expressed on B-cells, dendritic cells, and certain monocytes/macrophages, structurally resembling Toll-like receptors (TLRs) that plays a role in modulating immune responses. While ressembling a TLR, lacks the intracellular TIR (Toll/IL-1R) signaling domain and thus does not directly transduce signals. Instead, modulates immune responses, often in conjunction with other TLRs. For example, in cooperation with MD-1/LY86, interacts directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligand.

Subunit / interactions. M-shaped tetramer of two CD180-LY86 heterodimers. Interacts with TLR4, this interaction inhibits TLR4-mediated signaling pathway upon ligand binding.

Subcellular location. Cell membrane.

Tissue specificity. Expressed mainly on mature peripherical B cells. Detected in spleen, lymph node and appendix. Not detected in pre-B and -T cells.

Similarity. Belongs to the Toll-like receptor family.

RefSeq proteins (1): NP_005573* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR041281	LRR_11	Repeat

Pfam: PF13855, PF18831

UniProt features (104 total): strand 30, repeat 19, turn 16, helix 13, glycosylation site 11, sequence variant 7, topological domain 2, domain 2, signal peptide 1, chain 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3B2D	X-RAY DIFFRACTION	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99467-F1	93.27	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (11): 34, 53, 70, 78, 201, 234, 244, 394, 402, 451, 573

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-168898	Toll-like Receptor Cascades

MSigDB gene sets: 189 (showing top): TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_B_CELL_ACTIVATION, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_B_CELL_PROLIFERATION, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_LEUKOCYTE_PROLIFERATION, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_REGULATION_OF_LIPOPOLYSACCHARIDE_MEDIATED_SIGNALING_PATHWAY

GO Biological Process (8): B cell proliferation involved in immune response (GO:0002322), inflammatory response (GO:0006954), positive regulation of lipopolysaccharide-mediated signaling pathway (GO:0031666), B cell proliferation (GO:0042100), innate immune response (GO:0045087), cellular response to lipopolysaccharide (GO:0071222), immune system process (GO:0002376), lipopolysaccharide-mediated signaling pathway (GO:0031663)

GO Molecular Function (3): lipopolysaccharide immune receptor activity (GO:0001875), signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (5): nucleoplasm (GO:0005654), nucleolus (GO:0005730), plasma membrane (GO:0005886), mitotic spindle (GO:0072686), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Toll-like Receptor Cascades	1
Immune System	1
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune response	2
lipopolysaccharide-mediated signaling pathway	2
nuclear lumen	2
cellular anatomical structure	2
B cell activation involved in immune response	1
B cell proliferation	1
defense response	1
positive regulation of response to biotic stimulus	1
positive regulation of signal transduction	1
regulation of lipopolysaccharide-mediated signaling pathway	1
positive regulation of response to external stimulus	1
B cell activation	1
lymphocyte proliferation	1
defense response to symbiont	1
response to lipopolysaccharide	1
cellular response to molecule of bacterial origin	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
biological_process	1
cell surface receptor signaling pathway	1
cellular response to lipopolysaccharide	1
lipopolysaccharide binding	1
pattern recognition receptor activity	1
molecular transducer activity	1
binding	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
spindle	1

Protein interactions and networks

STRING

1510 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD180	LY86	O95711	999
CD180	LY96	Q9Y6Y9	861
CD180	TLR2	O60603	853
CD180	TLR4	O00206	813
CD180	CD19	P15391	576
CD180	GHITM	Q9H3K2	552
CD180	CLEC9A	Q6UXN8	542
CD180	PROSER2	Q86WR7	539
CD180	TLR1	Q15399	507
CD180	RIGI	O95786	500
CD180	CD37	P11049	492
CD180	CD74	P04233	482
CD180	CD79A	P11912	477
CD180	CD48	P09326	476
CD180	ITGAM	P11215	476
CD180	FATE1	Q969F0	476

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CD180	LY86	psi-mi:“MI:0915”(physical association)	0.540
CD180	LY86	psi-mi:“MI:0407”(direct interaction)	0.540

BioGRID (3): CD180 (Affinity Capture-Western), LY86 (Affinity Capture-Western), CD180 (Affinity Capture-MS)

ESM2 similar proteins: A4D1F6, A4IIK1, A6H6A4, A6NIV6, A6NM36, C0STK7, D3ZXS4, F1R6I3, F6R2G2, P14605, Q09562, Q32KX5, Q38SD2, Q3TX51, Q3UHC2, Q3UV48, Q3ZC49, Q4R6F0, Q54AX5, Q58A48, Q5G5E0, Q62192, Q65YW8, Q65Z91, Q66HD6, Q6AXL3, Q6GLE8, Q6GM71, Q6R5N8, Q6ZNQ3, Q7Z2Q7, Q86X40, Q8BGI7, Q8C0R9, Q8N456, Q8VDB8, Q96DD0, Q99467, Q99MB1, Q9BYS8

Diamond homologs: C0STK7, O93233, P02750, P58727, Q5PQV5, Q8C110, Q99467, Q9H5Y7, Q9MYW3, A3KNN3, A4IIW9, A6NJW4, A8WHP9, E9Q7T7, O02833, O15335, O55226, O70210, O75093, O75094, O88279, O88280, O94769, O94813, P0C6S8, P24014, P35858, P35859, P56400, P70389, Q27972, Q5FW85, Q5RDJ4, Q62192, Q66HV9, Q6NUI6, Q6R5N8, Q7M6Z0, Q80TR4, Q80WD0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

106 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	91
Likely benign	6
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

390 predictions. Top by Δscore:

Variant	Effect	Δscore
5:67196547:CTCA:C	donor_loss	1.0000
5:67196548:TCA:T	donor_loss	1.0000
5:67196549:CA:C	donor_loss	1.0000
5:67184587:T:C	acceptor_gain	0.9900
5:67185845:ACAT:A	donor_loss	0.9900
5:67185846:CATA:C	donor_loss	0.9900
5:67185847:ATA:A	donor_loss	0.9900
5:67185848:TAC:T	donor_loss	0.9900
5:67185849:ACC:A	donor_loss	0.9900
5:67186014:CTTT:C	acceptor_gain	0.9900
5:67186017:TC:T	acceptor_loss	0.9900
5:67186018:C:CA	acceptor_loss	0.9900
5:67186018:C:CC	acceptor_gain	0.9900
5:67196550:A:AC	donor_gain	0.9900
5:67196551:C:CC	donor_gain	0.9900
5:67196551:CCT:C	donor_gain	0.9900
5:67184585:CCT:C	acceptor_gain	0.9800
5:67185849:A:AC	donor_gain	0.9800
5:67185850:C:CC	donor_gain	0.9800
5:67186016:TT:T	acceptor_gain	0.9800
5:67184583:CACC:C	acceptor_loss	0.9700
5:67184586:CTT:C	acceptor_loss	0.9700
5:67184587:T:TC	acceptor_gain	0.9700
5:67185850:CCTA:C	donor_gain	0.9700
5:67186015:TTT:T	acceptor_gain	0.9700
5:67196551:CCTCA:C	donor_gain	0.9700
5:67184583:CACCT:C	acceptor_gain	0.9600
5:67186021:A:C	acceptor_gain	0.9600
5:67184584:ACCT:A	acceptor_gain	0.9500
5:67184585:CCTT:C	acceptor_gain	0.9500

AlphaMissense

4432 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:67184510:A:C	N111K	0.971
5:67184510:A:T	N111K	0.971
5:67184454:A:G	L130P	0.962
5:67183023:C:G	C607S	0.960
5:67183024:A:T	C607S	0.960
5:67185919:A:C	N63K	0.960
5:67185919:A:T	N63K	0.960
5:67184366:G:C	N159K	0.956
5:67184366:G:T	N159K	0.956
5:67183641:A:G	L401S	0.953
5:67183101:C:G	C581S	0.952
5:67183102:A:T	C581S	0.952
5:67183569:A:T	L425H	0.951
5:67184584:A:G	C87R	0.950
5:67184498:G:C	F115L	0.949
5:67184498:G:T	F115L	0.949
5:67184500:A:G	F115L	0.949
5:67183102:A:G	C581R	0.948
5:67184582:G:C	C87W	0.946
5:67184310:A:G	L178P	0.945
5:67184294:A:C	N183K	0.944
5:67184294:A:T	N183K	0.944
5:67183422:A:G	L474P	0.941
5:67183635:A:G	L403P	0.941
5:67183794:A:G	L350P	0.940
5:67183122:A:G	L574S	0.937
5:67183070:C:A	W591C	0.936
5:67183070:C:G	W591C	0.936
5:67183494:A:G	L450P	0.936
5:67185922:A:C	F62L	0.936

dbSNP variants (sampled 300 via entrez): RS1000525980 (5:67194825 A>C), RS1000688290 (5:67188604 T>C), RS1001040593 (5:67189666 T>C), RS1001097078 (5:67189268 T>C), RS1001737672 (5:67189141 C>G), RS1001928740 (5:67195454 G>A), RS1002487700 (5:67183527 C>T), RS1002551860 (5:67191442 G>A,T), RS1002620673 (5:67184509 G>A), RS1002624777 (5:67190049 A>G,T), RS1002704638 (5:67190592 G>A), RS1002758252 (5:67190956 G>A,T), RS1003225705 (5:67180462 C>A), RS1003339266 (5:67197086 G>A), RS1003442374 (5:67180276 C>T)

Disease associations

OMIM: gene MIM:602226 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003875_51	Gut microbiota (bacterial taxa)	4.000000e-09
GCST005184_10	Common carotid intima-media thickness in HIV infection	1.000000e-06
GCST006269_1226	General cognitive ability	5.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement
EFO:0007883	taxonomic microbiome measurement
EFO:0004337	intelligence

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	decreases expression, increases expression	3
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
triphenyl phosphate	affects expression	1
sulforaphane	decreases expression	1
sodium arsenite	increases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, decreases expression, affects response to substance	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
(+)-JQ1 compound	decreases expression	1
Norethindrone Acetate	affects cotreatment, decreases expression	1
Air Pollutants, Occupational	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	increases abundance, decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Dronabinol	increases expression	1
Aflatoxin B1	increases methylation	1
Fluorescein-5-isothiocyanate	affects binding	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.